Compare Flagstar Bank NA (FLG) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Summit Therapeutics Inc — how do they compare? Flagstar Bank NA trades at $14.2 (market cap $5.89B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 2× Flagstar Bank NA's market cap, and Flagstar Bank NA pays a 0.28% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| FLG | SMMT | |
|---|---|---|
Market Cap | $5.89B | $12.06B |
Sector | Financials | Health |
52-Week High | $15.36 | $26.98 |
52-Week Low | $10.72 | $12.55 |
Dividend Yield | 0.28% | — |
Enterprise Value | — | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLG trades at $14.20, up 1.36% today, with a bullish technical signal and analyst consensus price target of $16.85 suggesting 19% upside. Recent Q2 2026 earnings missed estimates, but the bank reported its third consecutive profitable quarter, supported by loan growth and cost controls. A $250 million share repurchase program and strategic operational enhancements signal management confidence in long-term value.
The outlook is cautiously optimistic, with profitability improving and valuation attractive at a P/B of 0.77. Risks include earnings volatility, competitive pressures, and economic sensitivity. Institutional sentiment leans bullish, with no sell ratings, though execution on guidance remains key for sustained momentum.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
